Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir

Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruse...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Journal of infectious diseases Ročník 204; číslo 11; s. 1811
Hlavní autori:	Canducci, Filippo, Ceresola, Elisa R, Boeri, Enzo, Spagnuolo, Vincenzo, Cossarini, Francesca, Castagna, Antonella, Lazzarin, Adriano, Clementi, Massimo
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.12.2011
Predmet:	Amino Acid Substitution - genetics Anti-HIV Agents - pharmacology Drug Resistance, Viral - genetics Heterocyclic Compounds, 3-Ring - pharmacology HIV Infections - drug therapy HIV Infections - virology HIV Integrase - genetics HIV Integrase Inhibitors - pharmacology HIV-1 - drug effects HIV-1 - enzymology HIV-1 - genetics Humans Inhibitory Concentration 50 Microbial Sensitivity Tests Mutation Phenotype Pyrrolidinones - pharmacology Raltegravir Potassium
ISSN:	1537-6613, 1537-6613
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!